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Objective: Right heart catheterization is performed in patients with pulmonary arterial
hypertension to determine the severity of disease and their pulmonary vascular reactivity.
The acute pulmonary vascular effect of inhaled nitric oxide is frequently used to identify
patients who will respond favorably to long-term vasodilator therapy. This study sought to
determine whether the acute pulmonary vascular effects of oxygen with nitric oxide and
intravenous sildenafil are similar.
Methods: A retrospective, descriptive study of 13 individuals with pulmonary hyperten-
sion who underwent heart catheterization and acute vasodilator testing was performed.
The hemodynamic measurements during five phases (21–53% oxygen, 100% oxygen,
100% oxygen with 20 ppm nitric oxide, 21–51% oxygen, and 21–51% oxygen with 0.05–
0.29 mg/kg intravenous sildenafil) of the procedures were compared using analysis of
variance. A linear regression analysis and a Bland Altman plot were used to compare the
percent change in mean pulmonary arterial pressure and the percent change in pulmonary
vascular resistance from baseline with oxygen and nitric oxide, and from baseline with
sildenafil.
Results: Mean pulmonary arterial pressure and pulmonary vascular resistance acutely
decreased with 100% oxygen with nitric oxide and 21–51% oxygen with sildenafil. Pul-
monary blood flow during sildenafil was greater than pulmonary blood flow during 100%
oxygen and 100% oxygen with nitric oxide.The pH, right atrial pressure, and left atrial pres-
sure did not change during the five phase of heart catheterization. Mean pulmonary arterial
pressure (millimeter of mercury, mean± standard error of the mean) was 38±4 during 21–
53% oxygen, 32±3 during 100% oxygen, 29±2 during 100% oxygen with nitric oxide,
37±3 during 21–51% oxygen, and 32±2 during 21–51% oxygen with sildenafil.There was
not a significant correlation between the percent change in pulmonary vascular resistance
from baseline with oxygen and nitric oxide, and from baseline with sildenafil (r2=0.011,
p=0.738). The Bland Altman analysis demonstrated statistical agreement between the
effects of oxygen with nitric oxide and sildenafil. However, differences were large enough
to limit the interchangeable use of these vasodilators in a clinical setting.
Conclusion: Oxygen with nitric oxide and sildenafil decreased pulmonary vascular resis-
tance. However, the pulmonary vascular effects of oxygen and nitric oxide do not reli-
ably predict the acute response to sildenafil. Additional studies are needed to determine
whether the acute response to sildenafil can be used to predict the long-term response to
treatment with an oral phosphodiesterase V inhibitor.
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Pulmonary hypertension is a serious disease associated with con-
striction, cellular hypertrophy and proliferation, inflammation,
and in situ thrombosis of the small vessels of the pulmonary cir-
culation (1). Patients often respond more favorably to long-term
treatment if their pulmonary vascular resistance decreases dur-
ing acute vasodilator testing during heart catheterization (2–4).
However, the response to short acting agents may not predict the
long-term response to medications that act on different pathways
of signal transduction. The acute hemodynamic effects of oxygen
with nitric oxide and diltiazem were not similar in a previous study
of patients with pulmonary hypertension (5).
Sildenafil is a phosphodiesterase V inhibitor that increases the
6-min walk performance of adults with pulmonary arterial hyper-
tension (6). Sildenafil also improved 6-min walk performance
and hemodynamic measurements of children with pulmonary
hypertension (7). However, low-dose sildenafil failed to improve
exercise performance short-term, and high-dose sildenafil was
potentially associated with a decrease in long-term survival in a
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randomized,placebo-controlled study of children with pulmonary
arterial hypertension (8). These studies did not report whether
patients with a favorable response to acute vasodilator testing had
a better response to sildenafil long-term. At Primary Children’s
Hospital, patients with pulmonary hypertension typically undergo
an evaluation of pulmonary vascular reactivity with supplemen-
tal oxygen, inhaled nitric oxide, and at least one additional agent
during heart catheterization. Nitric oxide and sildenafil decrease
pulmonary vascular resistance through a common pathway. This
study sought to compare the acute effects of inhaled nitric and the
acute effects of intravenous sildenafil in patients with pulmonary
hypertension.
METHODS
The Institutional Review Board of the University of Utah approved
this retrospective study. The records of patients who underwent
acute pulmonary vasodilator testing with supplemental oxygen,
inhaled nitric oxide, and intravenous sildenafil were reviewed.
At Primary Children’s Hospital, hemodynamic measurements are
performed while patients are breathing enough supplemental oxy-
gen to achieve an oxygen saturation greater than 87%, 100%
oxygen, 100% oxygen with 20 parts per million (ppm) nitric oxide,
21–100% oxygen, and 21–100% oxygen with intravenous dilti-
azem, intravenous sildenafil, or intravenous epoprostenol. The
severity of disease and the acute response to oxygen with nitric
oxide are used to determine whether to evaluate the response to
diltiazem, sildenafil, or epoprostenol. Patients with mild to mod-
erate pulmonary hypertension or a reasonably good response to
oxygen with nitric oxide are usually evaluated with 21–30% oxygen
and diltiazem or sildenafil. Patients with moderate to severe pul-
monary hypertension and a limited response to oxygen with nitric
oxide are usually evaluated with 100% oxygen and epoprostenol.
In this study, an estimate of 100% oxygen was administered at
a flow rate of 15 L/min with a non-rebreathing facemask (one
patient) or an inspired fraction of approximately 1.0 through an
endotracheal tube. The dose of nitric oxide was held constant at
20 ppm during each study because the pulmonary vasodilatory
effects of 12 and 60 ppm nitric oxide were similar in a previous
study (9). Nitric oxide was administered with oxygen because the
vasodilatory effects of these agents may be additive (3, 9–11). The
dose of intravenous sildenafil has been somewhat arbitrary, begin-
ning with a dose of 0.05–0.15 mg/kg followed by additional doses
until a change in systemic blood pressure is observed. The mean
dose of intravenous sildenafil was 0.15 mg/kg with a median of
0.16 mg/kg and a range of 0.05–0.29 mg/kg. Cardiac index was
calculated by the Fick principle using estimated values of oxy-
gen consumption between 120 and 160 L/min-m2 based primarily
upon age, body surface area, and heart rate (12, 13). A consis-
tent estimate of oxygen consumption was used for all stages of
each evaluation of pulmonary vascular reactivity. Patients were
not given background therapy on the day of the procedure.
INCLUSION CRITERIA
Thirteen patients who were evaluated with intravenous sildenafil
during heart catheterization were included in this study. Patients
with a pulmonary hypertension classification in Group 1 or Group
3 were included in the study (14). All patients had a baseline mean
pulmonary arterial pressure greater than 25 mm Hg with a median
of 33 mm Hg and a range of 26–70 mm Hg and a pulmonary
vascular resistance greater than 3 units-m2 during initial baseline
measurements.
EXCLUSION CRITERIA
Patients with a pulmonary hypertension classification in Group 2,
Group 4, or Group 5 were not included in the study. Patients with
a functional single ventricle were excluded from this study.
ACUTELY RESPONSIVE PATIENTS
A favorable acute response to oxygen with nitric oxide or sildenafil
was defined with the following criteria:
• a 20% decrease in mean pulmonary arterial pressure from
baseline measurements (1),
• a 20% decrease in pulmonary vascular resistance from baseline
measurements,
• a decrease in mean pulmonary arterial pressure ≥10 mm Hg to
a value of <35 mm Hg for patients with a baseline mean pul-
monary arterial pressure≥35 mm Hg, or a decrease in mean pul-
monary arterial pressure to a value of <25 mm Hg for patients
with a baseline mean pulmonary arterial pressure<35 mm Hg.
Each criterion was considered because it is unknown whether
one is superior to the other, particularly for patients who have a
baseline mean pulmonary arterial pressure less than 40 mm Hg (3).
STATISTICAL ANALYSIS
Analysis of variance for repeated measures was used to identify sig-
nificant differences (p< 0.05) between inhaled nitric oxide with
supplemental oxygen and intravenous sildenafil for arterial blood
gases, heart rate, blood flow, vascular resistance, and blood pres-
sure. A linear regression analysis was used to identify potential
linear correlations between the pulmonary vasodilatory effects of
oxygen, oxygen with nitric oxide, and sildenafil. Numerical data are
expressed as mean± standard error of the mean. A Bland Altman
analysis was performed to compare the percent decrease in pul-
monary vascular resistance achieved with an acute trial of oxygen
with nitric oxide and an acute trial of intravenous sildenafil.
RESULTS
DEMOGRAPHIC INFORMATION
There were 13 patients (7 female). The median age of patients
was 12 years with a range of 0.5–35 years. The diagnostic classifi-
cation of patients is listed in Table 1. Three of the patients with
Table 1 | Diagnostic classification of patients.
Number of patients
Pulmonary arterial hypertension
Idiopathic 1
Associated with
Congenital heart disease (repaired) 2
Congenital heart disease (not repaired) 3
Partial anomalous pulmonary venous return 1
Atrial septal defect 2
Connective tissue disease 2
Lung disease 5
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congenital heart disease and one of the patients with lung disease
have Down syndrome. Heart catheterization was performed when
a diagnosis of pulmonary hypertension was initially confirmed
in seven patients, and for follow-up evaluations of pulmonary
vascular reactivity in six patients. No patient had more than one
evaluation of pulmonary vascular reactivity included in this study.
Patients reside at altitudes of 1300–2000 m. Heart catheteriza-
tion was performed at an altitude of approximately 1500 m. An
anesthesiologist provided sedation for all patients. Assisted ven-
tilation was used to electively support 12 patients during heart
catheterization. There were no complications associated with the
procedures.
The median amount of supplemental oxygen during baseline 1
was 23% with a range of 21–53%. The median amount of supple-
mental oxygen during baseline 2 and the sildenafil phase was 23%
with a range of 21–51%.
PULMONARY VASCULAR REACTIVITY
The results of arterial blood gas,heart rate,blood flow,and vascular
resistance measurements are shown in Table 2. The mean pul-
monary arterial blood pressures, mean pulmonary arterial wedge
pressures, mean systemic arterial blood pressures, and mean right
atrial pressures during each stage of the hemodynamic evaluations
are shown in Figure 1. Oxygen with nitric oxide and sildenafil both
decreased pulmonary arterial pressure and pulmonary vascular
resistance in comparison to the preceding baseline measurements.
Sildenafil decreased systemic arterial pressure and systemic vascu-
lar resistance. The use of supplemental oxygen was associated with
a mild decrease in heart rate.
There was a significant correlation between the values of pul-
monary vascular resistance (r2= 0.861, p< 0.001) and mean pul-
monary arterial pressure (r2= 0.800, p< 0.001) during baseline 1
and baseline 2. There was a significant correlation between the val-
ues of pulmonary vascular resistance (r2= 0.869, p< 0.001) and
mean pulmonary arterial pressure (r2= 0.680, p< 0.001) during
oxygen and sildenafil. There was a significant correlation between
the values of pulmonary vascular resistance (r2= 0.782,p< 0.001)
and mean pulmonary arterial pressure (r2= 0.662, p< 0.001)
during oxygen with nitric oxide and sildenafil. Despite these
significant correlations, there was not a significant correlation
between the percent change in pulmonary vascular resistance
(r2= 0.011, p= 0.738) and the percent change in mean pul-
monary arterial pressure (r2= 0.170, p= 0.161) between baseline
1 and oxygen with nitric oxide and baseline 2 and sildenafil. The
percent decrease in pulmonary vascular resistance with oxygen
and nitric oxide and the percent decrease in pulmonary vas-
cular resistance with sildenafil for each patient are shown in
Figure 2.
The plot for the Bland Altman analysis is shown in Figure 3. All
of the values for the differences in percent decrease in pulmonary
vascular resistance fall within the 95% confidence intervals (±1.96
standard deviations). This suggests that there is statistical agree-
ment between the results of acute vasodilator testing with oxygen
with nitric oxide and sildenafil. Unfortunately, the difference for
the percent decrease in pulmonary vascular resistance for the two
tests exceeds 20% for 7 of the 13 patients. Plots for comparisons in
differences between the decrease mean pulmonary artery pres-
sure and percent decrease in mean pulmonary artery pressure
also showed statistical agreement between the results of acute
vasodilator testing with oxygen with nitric oxide and sildenafil.
The difference in the decrease in mean pulmonary arterial pres-
sure exceeded 5 mm Hg in 4 of the 13 patients. The difference in
the percent decrease in mean pulmonary arterial pressure exceeded
20% in 3 of the 13 patients.
The number of responders using each criterion for a favor-
able acute response to oxygen with nitric oxide or sildenafil is
shown in Table 3. More responders to sildenafil were identified
if a 20% decrease in pulmonary vascular resistance was used as a
criterion because sildenafil seemed to increase pulmonary blood
flow. There were 7 patients who experienced a 20% decrease
in pulmonary vascular resistance with oxygen and nitric oxide
and 10 patients who experienced a 20% decrease in pulmonary
vascular resistance with sildenafil. However, only four patients
had a 20% decrease in pulmonary vascular resistance with both
medications.
Patients were treated with the following agents long-term: one
patient with supplemental oxygen alone; two patients with a cal-
cium channel blocker; six patients with a phosphodiesterase V
inhibitor; one patient with an endothelin receptor antagonist; one
patient with a calcium channel blocker and a phosphodiesterase V
inhibitor; and two patients with a phosphodiesterase V inhibitor,
an endothelin receptor antagonist, and a prostacyclin analog.
Table 2 | Arterial blood gases, heart rate, blood flow, and vascular resistance.
Phase pH PO2, mm Hg HR, min−1 Qp, L/min-m2 Rp, units-m2 Rs, units-m2
Baseline 1 7.41±0.02 62±4 82±6 3.53±0.33 8.7±1.5 17.7±1.4
100% Oxygen 7.42±0.01 255±32a 75±6 3.14±0.25 7.7±1.3 20.1±1.3
100% Oxygen with Nitric Oxide 7.42±0.02 287±31a,b 75±6b 3.25±0.27b 6.1±1.0a 19.4±1.2b
Baseline 2 7.43±0.02 64±3 81±6 3.48±0.29 8.4±1.4 18.6±1.3
Sildenafil 7.41±0.01 58±3 83±6 4.00±0.38 5.7±0.8a 14.0±0.9a
n=13, mean±SEM.
HR, heart rate; PO2, arterial oxygen tension; Qp, pulmonary blood flow; Rp, pulmonary vascular resistance index; Rs, systemic vascular resistance index.
aSignificant difference in comparison to the preceding baseline measurement, p<0.05.
bSignificant difference between measurements for oxygen with nitric oxide and sildenafil, p<0.05.
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FIGURE 1 | Influence of vasodilatory agents on pulmonary and
systemic arterial pressures. The mean pulmonary arterial pressures and
the mean systemic arterial pressures for 13 patients during five phases of
heart catheterization are shown. The mean pulmonary arterial pressure was
lower during oxygen with nitric oxide and baseline 1 (*p<0.05). The mean
systemic arterial pressure during treatment with an intravenous infusion of
sildenafil was lower than the mean systemic arterial pressure during
oxygen, oxygen with nitric oxide, and baseline 2 (*p<0.05). The
corresponding mean pulmonary arterial wedge pressures are shown in
black with the mean pulmonary arterial pressures. The corresponding right
atrial pressures are shown in black with the mean systemic arterial
pressures.
DISCUSSION
This study describes the acute pulmonary vascular effects of
supplemental oxygen, oxygen with inhaled nitric oxide, and intra-
venous sildenafil for a subset of patients who underwent heart
catheterization for pulmonary arterial hypertension at a children’s
hospital. An adequate dose of sildenafil was used to significantly
decrease systemic vascular resistance. Oxygen with nitric oxide and
sildenafil both decreased pulmonary vascular resistance. However,
the magnitude of the response to these agents differed for individ-
ual patients. These results suggest that the response to oxygen with
nitric oxide and the response to sildenafil may not be sufficiently
consistent to use the tests interchangeably in a clinical setting.
Nitric oxide and sildenafil decrease pulmonary vascular resis-
tance through a common pathway. It is unclear why some patients
respond more favorably to one agent. Nitric oxide stimulates
soluble guanylate cyclase to produce cyclic-GMP. It is possible
that sildenafil is less effective in patients with severe endothelial
FIGURE 2 | Differences in the pulmonary vasodilatory effects for oxygen
with nitric oxide and sildenafil. The percent decrease in pulmonary
vascular resistance with oxygen and nitric oxide and the percent decrease
in pulmonary vascular resistance with sildenafil for each patient are shown.
There is no linear correlation for the pulmonary vasodilatory effects of these
agents (r 2 =0.011, p=0.738). There is no correlation for patients with an
initial baseline mean pulmonary arterial pressure ≥35 mm Hg (dark circles)
or for patients with an initial baseline mean pulmonary arterial pressure
<35 mm Hg (light circles). Rp, pulmonary vascular resistance index.
dysfunction and a limited amount of endogenous nitric oxide
production. The effects of inhaled nitric oxide and sildenafil may
also be limited by abnormalities in other aspects of this pathway
of signal transduction (15).
Heart catheterization can safely be used to evaluate the hemo-
dynamic effects of more than one agent. This allows more infor-
mation to be obtained concerning the vasodilatory potential of
individual patients. The United States Food and Drug administra-
tion has warned concerning the use of sildenafil in young patients.
It may be helpful to use the acute effects of sildenafil when con-
sidering the potential risks and benefits of treatment with an oral
phosphodiesterase V inhibitor. It seems reasonable to select an
agent for long-term therapy if it acutely decreases pulmonary vas-
cular resistance. However, additional studies will be needed to
determine whether a favorable or unfavorable acute vasodilatory
response reliably predicts the outcome of long-term therapy. Most
clinical trials have failed to report whether the results of acute
vasodilator testing corresponded with the outcome of treatment.
This study was too small to evaluate whether there was a cor-
relation between the acute response to oxygen, nitric oxide, or
sildenafil and the long-term efficacy of treatment with a phos-
phodiesterase V inhibitor. There were only four patients who were
treated long-term with a phosphodiesterase V inhibitor alone.
Some of the definitions related to the hemodynamic evalu-
ation of patients with pulmonary hypertension need additional
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FIGURE 3 | A Bland Altman plot for the comparison between
differences in the percent decrease in pulmonary vascular resistance
for oxygen with nitric oxide and sildenafil. There is statistical evidence of
agreement between the pulmonary vasodilatory effects for oxygen with
nitric oxide and sildenafil. The mean difference between the percent
decrease in pulmonary vascular resistance for oxygen with nitric oxide and
sildenafil is −2.8 (solid line). All values fall within the 95% confidence
intervals (±1.96 standard deviations, dashed lines). However, the difference
between the percent decrease for oxygen with nitric oxide and sildenafil
exceeds 20% for 7 of the 13 patients. This appears to be true for patients
with an initial baseline mean pulmonary arterial pressure ≥35 mm Hg (dark
circles) and for patients with an initial baseline mean pulmonary arterial
pressure <35 mm Hg (light circles). Rp, pulmonary vascular resistance
index.
Table 3 | Number of responsive patients.
Oxygen with
nitric oxide
Sildenafil
20% decrease in MPAP 6 1
20% decrease in Rp 7 10
MPAP ≥35 mm Hg, n=6
10 mm Hg decrease in MPAP
to a value <35 mm Hg
2 0
MPAP <35 mm Hg, n=7
Decrease in MPAP <25 mm Hg 4 1
MPAP, mean pulmonary arterial pressure; Rp, pulmonary vascular resistance
index.
consideration. Patients with a pulmonary vascular resistance of
3 units-m2 typically have a mean pulmonary arterial pressure
less than 25 mm Hg unless the left atrial pressure is elevated.
A decrease in mean pulmonary arterial pressure of 10 mm Hg
to a value less than 40 mm Hg may be an appropriate method
for acute vasodilator testing in patients with moderate to severe
pulmonary arterial pressure. However, it is not useful for patients
with a mean pulmonary arterial pressure less than 35 mm Hg if
a mean pulmonary arterial pressure of 25 mm Hg might be con-
sidered normal. Many patients with a mean pulmonary arterial
pressure near 25 mm Hg have a pulmonary vascular resistance
greater than 5 units-m2. It may be more appropriate to identify
acute responders to vasodilators by a 20% decrease in resistance or
pressure instead of a mere decrease in mean pressure below 25 mm
Hg. For this reason, several definitions for acute reactivity were
considered in this study. The clinical application of information
from acute vasodilator testing also deserves additional consider-
ation. For example, if a patient with a baseline mean pulmonary
arterial pressure of 50 mm Hg experienced a 15 mm Hg decrease
with nitric oxide, a 5 mm Hg decrease with diltiazem, and a 12 mm
Hg decrease with sildenafil; would it be appropriate to start long-
term therapy with a calcium channel blocker alone? Patients with
this profile of pulmonary vascular reactivity exist, particularly in
a pediatric setting. The mortality and morbidity of pulmonary
hypertension is related to the patient’s pulmonary arterial pres-
sure and heart function. It is important to identify agents that
decrease pulmonary arterial pressure in our patients at the onset,
and throughout the course, of therapy.
LIMITATIONS
This is a retrospective descriptive study with the following
limitations:
• A relatively small number of patients were included in the study.
Only one patient has idiopathic pulmonary arterial hyperten-
sion. Even though the results of acute vasodilator testing have
seemingly been influenced more by the severity of disease than
the cause of disease at Primary Children’s Hospital. The results
of this study may not be relevant for all causes of pulmonary
vascular disease.
• This study only included patients who had some response
to supplemental oxygen with nitric oxide. It did not include
patients with severe pulmonary hypertension who had no
response because they were typically evaluated with intravenous
epoprostenol instead of sildenafil. It is unknown whether a sub-
group of patients may be responsive to sildenafil, yet fail to
respond oxygen with nitric oxide.
• It is unknown whether a maximal pulmonary vasodilatory
response occurred with the amounts of oxygen, nitric oxide,
and sildenafil that were used during acute vasodilator testing in
this study. However, a sufficient amount of sildenafil was used
to significantly decrease the mean systemic arterial pressure and
systemic vascular resistance.
• Levels of cyclic-GMP were not measured to determine whether
the effects of oxygen, nitric oxide, and sildenafil correlated with
this messenger of signal transduction.
• There were potential errors in the calculations of blood flow and
vascular resistance using assumed and consistent values of oxy-
gen consumption. For this reason, the effects of each agent on
direct measurements of mean pulmonary arterial pressure and
mean systemic pressure were also reported. Three patients had
an atrial level shunt that could have influenced the pulmonary
arterial pressure.
• It is possible that sildenafil would have decreased the mean pul-
monary arterial pressure or pulmonary vascular resistance more
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with 100% oxygen than with 21–51% oxygen. A lower amount
of oxygen was used with sildenafil in order to avoid obscuring a
response to sildenafil by the effects of oxygen.
• This study was performed at a mildly increased altitude of
1500 m. The patients also reside at a mildly to moderately
increased altitude. Results may be different if hemodynamic
measurements are performed at a different altitude.
In conclusion, supplemental oxygen with inhaled nitric oxide
and sildenafil both acutely decrease pulmonary vascular resistance
in some patients with pulmonary hypertension. Sildenafil also
acutely increases pulmonary blood flow and decreases systemic
vascular resistance. The magnitudes of the pulmonary vasodila-
tory effects of oxygen with nitric oxide and sildenafil were dif-
ferent in individual patients. This discrepancy suggests that acute
vasodilator testing with oxygen and nitric oxide should not be
used as a surrogate to predict the pulmonary vasodilatory effect of
a phosphodiesterase V inhibitor.
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